Ra Capital Management, L.P. Ascendis Pharma A/S Transaction History

Ra Capital Management, L.P.

$6.17 Billion
Q4 2024

A detailed history of Ra Capital Management, L.P. transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Ra Capital Management, L.P. holds 10,112,744 shares of ASND stock, worth $1.54 Billion. This represents 22.55% of its overall portfolio holdings.

Number of Shares

10,112,744

Previous 9,710,428 4.14%

Holding current value

$1.54 Billion

Previous $1.45 Billion 4.0%

% of portfolio

22.55%

Previous 20.22%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$122.0 - $146.6 $49.1 Million - $59 Million	402,316 Added 4.14%	10,112,744 $1.39 Billion
Q3 2024 Nov 14, 2024	SELL	$113.0 - $153.43 $45 Million - $61.1 Million	-397,972 Reduced 3.94%	9,710,428 $1.45 Billion
Q2 2024 Aug 14, 2024	BUY	$121.07 - $153.67 $1.22 Billion - $1.55 Billion	10,108,400 New	10,108,400 $1.38 Billion
Q1 2024 May 15, 2024	BUY	$123.45 - $159.4 $123,450 - $159,400	1,000 Added 0.01%	10,108,400 $1.53 Billion
Q4 2023 Feb 14, 2024	BUY	$86.1 - $127.36 $870 Million - $1.29 Billion	10,107,400 New	10,107,400 $1.27 Billion
Q3 2023 Nov 14, 2023	SELL	$86.5 - $103.97 $43.8 Million - $52.6 Million	-505,802 Reduced 4.51%	10,719,555 $1 Billion
Q2 2023 Aug 14, 2023	BUY	$69.96 - $97.84 $299 Million - $418 Million	4,268,178 Added 61.35%	11,225,357 $1 Billion
Q4 2022 Feb 14, 2023	SELL	$99.42 - $131.97 $60.7 Million - $80.6 Million	-610,721 Reduced 8.07%	6,957,179 $850 Million
Q4 2021 Feb 14, 2022	BUY	$127.1 - $169.66 $22.9 Million - $30.5 Million	180,000 Added 2.44%	7,567,900 $1.02 Billion
Q3 2021 Nov 15, 2021	BUY	$112.67 - $176.92 $65.5 Million - $103 Million	581,559 Added 8.54%	7,387,900 $1.18 Billion
Q2 2021 Aug 16, 2021	BUY	$121.62 - $145.29 $47.9 Million - $57.3 Million	394,113 Added 6.15%	6,806,341 $895 Million
Q1 2021 May 17, 2021	BUY	$124.92 - $173.33 $68.3 Million - $94.8 Million	546,890 Added 9.32%	6,412,228 $826 Million
Q4 2020 Feb 16, 2021	SELL	$151.2 - $182.76 $6.71 Million - $8.12 Million	-44,404 Reduced 0.75%	5,865,338 $978 Million
Q3 2020 Nov 16, 2020	BUY	$134.29 - $154.32 $134 Million - $154 Million	994,787 Added 20.24%	5,909,742 $912 Million
Q1 2020 May 15, 2020	BUY	$97.01 - $145.11 $70.8 Million - $106 Million	729,613 Added 17.43%	4,914,955 $553 Million
Q4 2019 Feb 14, 2020	BUY	$91.45 - $139.12 $4.84 Million - $7.36 Million	52,900 Added 1.28%	4,185,342 $582 Million
Q1 2019 May 15, 2019	SELL	$62.15 - $129.99 $6.72 Million - $14.1 Million	-108,094 Reduced 2.55%	4,132,442 $486 Million
Q1 2018 May 15, 2018	SELL	$38.98 - $68.04 $52.2 Million - $91.2 Million	-1,340,154 Reduced 24.01%	4,240,536 $277 Million
Q3 2017 Nov 14, 2017	BUY	$26.89 - $37.1 $150 Million - $207 Million	5,580,690	5,580,690 $202 Million

Others Institutions Holding ASND

# of Institutions

236

Shares Held

60.2M

Call Options Held

80.3K

Put Options Held

216K

View Full List

About Ascendis Pharma A/S

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $8.51B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

More about ASND

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ra Capital Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Ra Capital Management, L.P. with notifications on news.

Account

Ra Capital Management, L.P. Ascendis Pharma A/S Transaction History